التفاصيل البيبلوغرافية
| العنوان: |
725-P: Reducing Hypoglycemic Risk during Postprandial Exercise with Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes: Announced and Unannounced Exercise. |
| المؤلفون: |
TAGOUGUI, SEMAH, TALEB, NADINE, SUPPERE, CORINNE, BOUKABOUS, INÈS, MESSIER, VIRGINIE, RABASA-LHORET, RÉMI |
| المصدر: |
Diabetes; 2019 Supplement, Vol. 68, pN.PAG-N.PAG, 1p |
| مستخلص: |
Background: Exercise-induced hypoglycemia is a major barrier for physical activity practice. Compared to conventional insulin therapy, closed-loop (CL) insulin delivery reduces hypoglycemic risk during post-absorptive exercise but has not been studied during postprandial exercise. Methods: Randomized crossover trial comparing 3 strategies for a postprandial (PP) exercise (90 min after breakfast) at 60% of VO2peak for 60min: 1) Unannounced exercise (Unann); 2) Announced exercise with reduced insulin bolus (Ann+RB): increased glucose target combined with a 33% meal bolus reduction); 3) Announced exercise with full bolus (Ann+FB): increased glucose target combined with usual meal bolus in 37 adults with type 1 diabetes. Results: Median percentage time spent in hypoglycemia (<70 mg/dl) was reduced with Ann+RB compared to Unann (Primary outcome; 0[0-0]% vs. 0[0-26]%; p<0.05). The drop in plasma glucose during exercise was smaller with Ann+RB (-5.5 ± 50.5 than with Ann+FB (-46.8 ± 52.2) and Unann (-43.2 ± 48.6) strategies (p <0.05). Accordingly, hypoglycemic events were reduced with Ann+RB (n=2) compared to Ann+FB (n=3) and Unann (n=9). However, Ann+BR strategy was associated with increased time in hyperglycemia (> 250mg/dl). Conclusion: Announcement of postprandial exercise to the closed-loop algorithm combined with meal bolus reduction reduced hypoglycemic risk, yet at the expense of mild increase in hyperglycemia. Disclosure: S. Tagougui: None. N. Taleb: None. C. Suppere: None. I. Boukabous: None. V. Messier: Other Relationship; Self; Eli Lilly and Company. R. Rabasa-Lhoret: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Research Support; Self; AstraZeneca, Janssen Pharmaceuticals, Inc., Novo Nordisk A/S. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diabetes is the property of American Diabetes Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder